accord
current
knowledg
mechan
rnai
initi
long
dsrna
process
rnase
iiilik
protein
known
dicer
protein
dicer
typic
contain
ntermin
rna
helicas
domain
rnabind
socal
piwiargonautezwil
paz
domain
two
rnase
iii
domain
dsrna
bind
domain
dsrbd
activ
lead
process
long
dsrna
nucleotid
doublestrand
sirna
two
base
overhang
phosphat
hydroxyl
group
result
sirna
duplex
incorpor
effector
complex
known
rnainduc
silenc
complex
risc
antisens
guid
strand
sirna
guid
risc
recogn
cleav
target
messeng
rna
mrna
sequenc
upon
adenosin
triphosph
atp
depend
unwind
doublestrand
sirna
molecul
rna
helicas
activ
catalyt
activ
risc
lead
mrna
degrad
mediat
endonucleas
argonaut
belong
highli
conserv
argonaut
famili
protein
argonaut
protein
kda
highli
basic
protein
contain
two
common
domain
name
piwi
paz
domain
piwi
domain
crucial
interact
dicer
contain
nucleas
activ
respons
cleavag
mrna
use
one
strand
sirna
duplex
guid
find
mrna
contain
complementari
sequenc
cleav
phosphodiest
backbon
base
rel
end
guid
strand
import
step
activ
risc
cleavag
sens
passeng
strand
remov
strand
complex
crystallographi
studi
analyz
interact
sirna
guid
strand
piwi
domain
reveal
nucleotid
constitut
seed
sequenc
direct
target
mrna
recognit
risc
mrna
cleav
presenc
unprotect
rna
end
fragment
mrna
cleav
degrad
intracellular
nucleas
longer
translat
protein
risc
recycl
subsequ
round
constitut
catalyt
process
lead
select
reduct
specif
mrna
molecul
correspond
protein
possibl
exploit
nativ
mechan
gene
silenc
purpos
regul
gene
choic
directli
deliv
sirna
effector
cell
tissu
activ
risc
produc
potent
specif
silenc
target
mrna
posttranscript
gene
silenc
ptg
induc
sirna
sequencespecif
cleavag
perfectli
complementari
mrna
also
accord
recent
discoveri
endogen
posttranscript
regulatori
mechan
one
mechan
mediat
microrna
mirna
function
natur
occur
small
noncod
rna
requir
partial
complementari
target
bind
target
mrna
untransl
region
utr
mirna
act
guid
sequenc
regul
express
multipl
gene
often
function
relat
furthermor
translat
mani
mrna
regul
multipl
differ
mirna
critic
factor
coordin
develop
differenti
function
cell
tissu
estim
hundr
molecul
human
approxim
mirna
identifi
human
genom
believ
regul
express
human
gene
prevent
translat
mrna
protein
mirna
aris
class
ii
rna
polymeras
transcript
term
primari
mirna
primirna
vari
length
hundr
base
ten
kilobas
signific
secondari
structur
primirna
recogn
microprocessor
complex
consist
protein
drosha
digeorg
syndrom
critic
region
gene
cleav
primirna
nucleotid
hairpin
contain
overhang
end
precursor
pre
mirna
export
nucleu
cytoplasm
protein
exportin
process
dicercontain
complex
nucleotid
imperfect
dsrna
duplex
constitut
matur
mirna
process
dicer
complex
consist
dicer
hiv
transactiv
respons
rnabind
protein
trbp
protein
activ
interferoninduc
protein
kinas
pact
mirna
duplex
assembl
risc
howev
mirna
duplex
almost
alway
asymmetr
complet
complementari
antisens
stretch
nucleotid
happen
sirna
mechan
select
one
strand
complet
clear
one
strand
load
risc
imperfect
sequenc
complementar
strand
mirna
might
prevent
cleav
passeng
strand
instead
unwound
discard
remain
strand
guid
risc
utr
mrna
lead
repress
protein
express
number
mechan
often
accompani
mrna
degrad
cytoplasm
compart
known
process
bodi
pbodi
mirna
share
complet
sequenc
complementar
target
sequenc
instead
direct
cleavag
risc
activ
specif
stretch
matur
mirna
includ
first
nucleotid
end
must
complet
complementar
target
order
obtain
effect
silenc
wherea
mismatch
nucleotid
end
better
toler
commerci
avail
system
therapeut
initi
aim
mimick
mechan
rnai
make
use
dna
vector
construct
viral
particl
code
longterm
stabl
short
hairpin
rna
shrna
express
transcrib
rna
polymeras
ii
iii
promot
vivo
shrna
synthes
exogen
transfect
cell
doublestrand
region
shrna
form
though
hairpin
structur
intramolecular
hybrid
resembl
mirna
precursor
shrna
molecul
recogn
dicer
lead
format
sirna
homolog
target
mrna
main
differ
sirna
mediat
transient
silenc
concentr
cytoplasm
dilut
time
success
cell
divis
shrna
mediat
potent
stabl
silenc
effect
long
transcript
take
place
hand
obviou
problem
approach
one
encount
gene
therapi
relat
express
long
exogen
rna
shrna
also
enter
endogen
silenc
pathway
earlier
stage
sirna
higher
chanc
satur
natur
mirna
natur
pathway
recent
studi
sought
address
issu
show
possibl
avoid
least
safeti
concern
seek
local
express
shrna
use
vector
harbor
tissuespecif
polymeras
ii
promot
improv
toler
nevertheless
current
effort
rather
lean
toward
therapeut
use
synthet
sirna
mechan
action
describ
sirna
mirna
shrna
summar
figur
human
surviv
upon
infect
larg
depend
abil
immun
system
detect
pathogen
mount
appropri
protect
immun
respons
mani
immun
cell
abil
sens
presenc
microbi
organ
though
sever
famili
pattern
recognit
receptor
prr
mediat
recognit
conserv
microbi
structur
known
pathogenassoci
molecular
pattern
pamp
lipopolysaccharid
peptidoglycan
flagellin
capsular
structur
bacteri
dna
viral
rna
glycoprotein
activ
innat
immun
respons
normal
use
fight
viral
infect
lead
product
type
interferon
downregul
gene
express
induct
apoptosi
well
document
dsrna
longer
nucleotid
trigger
potent
immun
respons
howev
sirna
larg
circumv
problem
seem
small
induc
cellular
toxic
nevertheless
alway
appear
true
two
pathway
lead
activ
immun
respons
one
involv
recognit
cytosol
rnabind
protein
serinethreonin
protein
kinas
r
pkr
helicas
retino
acidinduc
protein
rigi
melanoma
differentiationassoci
protein
includ
three
member
tolllik
receptor
tlr
famili
detect
rna
molecul
also
trigger
sequencespecif
manner
recognit
seem
cell
specif
work
identifi
immunostimulatori
motif
mechan
interferon
respons
foreign
pathogen
nucleic
acid
great
relev
design
synthet
sirna
unwant
activ
immun
system
prevent
exampl
plasmacytoid
dendrit
cell
activ
via
endosom
tlr
specif
gurich
region
call
danger
motif
reminisc
immunostimulatori
cytosinephosphateguanin
cpg
motif
antisens
oligonucleotid
odn
give
danger
signal
cell
via
receptor
therefor
even
though
warn
signal
benefici
certain
situat
avoid
order
achiev
safe
therapeut
use
rnai
also
shown
vitro
sirna
potent
induc
interferon
respons
due
presenc
triphosph
moieti
sever
report
shown
presenc
phosphorothio
backbon
modif
within
sirna
use
avoid
bind
tlr
prevent
cytokin
induct
maintain
silenc
activ
minim
advers
effect
sirna
could
transfect
human
primari
cell
full
repertoir
immun
stimul
result
discard
elicit
interferon
respons
follow
care
vivo
analysi
gain
knowledg
immun
stimulatori
properti
rnai
highli
specif
result
watsoncrick
base
pair
interact
nevertheless
number
studi
demonstr
sirna
induc
gene
express
chang
wide
rang
seemingli
unrel
gene
although
microarray
studi
shown
chang
offtarget
mrna
usual
may
result
substanti
chang
protein
express
mirna
pathway
activ
rule
defin
mirna
target
still
fulli
understood
difficult
predict
given
sirna
elicit
offtarget
silenc
limit
sequenc
homolog
end
utr
offtarget
gene
might
suffic
induc
gene
silenc
target
specif
mirna
depend
region
call
seed
region
seed
sequenc
compris
nucleotid
end
guid
strand
mirna
thu
small
sequenc
homolog
enough
trigger
offtarget
effect
ote
chanc
find
complementari
region
entir
human
transcriptom
far
greater
would
desir
care
comparison
candid
guid
strand
sequenc
entir
transcriptom
attempt
avoid
long
stretch
homolog
might
reduc
risk
estim
approxim
possibl
within
code
sequenc
genom
uniqu
leav
one
everi
five
long
sirna
display
homolog
compar
given
mrna
snove
holen
perform
independ
investig
publish
sirna
sequenc
found
almost
oligonucleotid
potenti
trigger
unwant
ote
suggest
use
inappropri
program
basic
local
align
search
tool
blast
design
effect
oligonucleotid
lead
abund
ote
precis
homolog
stretch
six
seven
base
pair
necessari
detect
blast
would
elimin
detect
close
relat
sequenc
base
pair
could
one
two
mismatch
enough
allow
hybrid
offtarget
sequenc
addit
nonspecif
ote
limit
guid
strand
also
trigger
passeng
strand
incorpor
risc
bind
mrna
bear
total
partial
sequenc
homolog
risc
incorpor
favor
strand
least
tightli
bound
end
becom
activ
strand
strand
select
fact
manipul
design
sirna
destabil
end
guid
strand
eg
make
singl
nucleotid
substitut
end
duplex
alter
rel
bind
end
therebi
promot
incorpor
strand
passeng
risc
minim
potenti
ote
comparison
effect
sirna
use
differ
deliveri
method
also
shown
mani
ote
larg
depend
lipidbas
transfect
reagent
sirna
bioactiv
drug
reli
cellular
process
exert
function
face
risk
satur
endogen
pathway
may
case
rnaibas
drug
shrna
sirna
similar
mirna
precursor
dicer
process
respect
reli
endogen
mirna
machineri
achiev
target
silenc
therefor
mirna
pathway
might
becom
satur
high
dose
exogen
rna
one
way
adenovirus
avoid
potenti
host
rnai
antivir
activ
express
larg
quantiti
noncod
rna
stemloop
interfer
transport
nucleu
cytoplasm
bind
nuclear
karyopherin
therebi
inhibit
transport
subsequ
process
cellular
premirna
similar
process
report
describ
vivo
adenoassoci
virusencod
overexpress
liverdirect
shrna
satur
result
inhibit
endogen
premirna
nuclear
export
ultim
caus
death
strong
express
shrna
also
shown
induc
cytotox
primari
lymphocyt
wherea
shrna
express
use
weaker
promot
present
toxic
effect
robust
level
antisens
rna
emerg
shrna
express
system
caus
toxic
mous
brain
regardless
sequenc
export
function
mediat
requir
activ
synthet
sirna
howev
recent
report
shown
synthet
sirna
express
shrna
compet
endogen
mirna
transport
incorpor
risc
trbp
one
sensor
select
incorpor
guid
sequenc
interf
rna
thu
number
factor
alter
endogen
cellular
process
result
toxic
therefor
crucial
work
lowest
possibl
concentr
mitig
potenti
advers
effect
factor
may
also
set
limit
number
differ
sirna
use
simultan
one
target
cell
efficaci
sirna
individu
target
normal
depend
differ
factor
thermodynam
stabil
structur
featur
target
mrna
access
addit
positionspecif
determin
systemat
studi
target
efficaci
shown
optim
sirna
nucleotid
long
symmetr
dinucleotid
overhang
low
guaninecytosin
content
specif
nucleotid
certain
posit
exampl
featur
increas
sirna
efficaci
presenc
adenin
uracil
posit
adenosin
posit
uracil
posit
guanin
posit
uracil
adenin
posit
site
risc
mediat
cleavag
guanin
posit
andor
absenc
guanin
cytosin
posit
sens
strand
see
dykxhoorn
lieberman
full
review
topic
gener
enrich
adenosin
uracil
along
first
base
pair
sequenc
consequ
weak
hydrogen
bond
allow
risc
easili
unravel
doublestrand
duplex
load
guid
strand
sirna
duplex
also
thermodynam
flexibl
end
ie
posit
sens
strand
correl
silenc
efficaci
presenc
least
one
adenosineuracil
pair
region
would
decreas
intern
stabil
increas
silenc
efficaci
contrast
intern
repeat
palindrom
sequenc
decreas
silenc
potenti
sirna
anoth
consider
need
taken
account
design
sirna
sequenc
natur
target
sequenc
certain
circumst
prefer
includ
splice
variant
isoform
design
sirna
wherea
instanc
specif
left
similarli
attent
paid
choic
sequenc
within
code
region
target
gene
sequenc
gene
silenc
exclus
cytoplasm
process
good
news
take
establish
criteria
account
rnai
allow
almost
unrestrict
choic
target
computerbas
algorithm
help
design
optim
sirna
sequenc
given
gene
consid
properti
thermodynam
valu
sequenc
asymmetri
polymorph
contribut
rna
duplex
stabil
nevertheless
theoret
optim
sirna
requir
extens
test
achiev
high
silenc
efficaci
without
advers
effect
regard
issu
enhanc
stabil
sever
chemic
modif
describ
increas
halflif
sirna
includ
introduct
phosphorothio
bond
viral
sirna
deliveri
use
specif
downregul
express
gene
patholog
relev
especi
chronic
diseas
longterm
gene
silenc
desir
eg
neurodegen
disord
cancer
heart
failur
hiv
infect
achiev
use
gene
therapi
approach
short
hairpin
rna
express
cassett
stabli
integr
host
cell
genom
express
episom
retrovir
adenovir
adenoassoci
herp
viral
shrna
deliveri
system
success
use
silenc
gene
vitro
vivo
stabl
integr
mediat
lentivirusbas
vector
well
suit
applic
sinc
abl
transduc
divid
nondivid
cell
singer
colleagu
demonstr
intracrani
inject
lentivir
vector
express
shrna
target
amyloid
precursor
protein
cleav
enzym
significantli
reduc
amyloid
product
main
caus
neurodegener
alzheim
diseas
transient
express
without
genom
integr
provid
adenovirus
result
shortterm
gene
silenc
adenoassoci
virus
use
deliveri
specif
sirna
target
mutant
spinocerebellar
mous
model
show
reduct
express
could
improv
motor
coordin
restor
cerebellar
morpholog
sabbioni
cowork
use
herp
simplex
viru
type
base
vector
sirna
deliveri
mammalian
cell
use
human
polyomaviru
bk
bkv
transform
cell
model
system
abil
amplicon
vector
inhibit
express
bkvtantigen
demonstr
use
amplicon
vector
highli
effici
deliveri
sirna
molecul
abil
deliv
multipl
copi
may
constitut
use
tool
develop
novel
therapi
suckau
colleagu
use
rat
model
transaort
band
demonstr
rnaibas
therapi
use
rescu
heart
failur
restor
cardiac
function
intraven
inject
adenoassoci
viru
vector
target
phospholamban
key
regul
cardiac
homeostasi
cardiac
phospholamban
protein
reduc
suppress
sarcoplasm
reticulum
atpas
rescu
heart
failur
group
moreov
display
high
affin
myocardium
low
affin
liver
organ
hepatotox
mirna
deregul
summari
viral
deliveri
system
advantag
achiev
high
transfect
effici
due
inher
abil
virus
transport
genet
materi
cell
howev
viral
system
limit
load
capac
ie
genet
materi
rather
difficult
produc
larg
scale
addit
viral
system
pose
sever
safeti
risk
oncogen
potenti
via
insert
mutagenesi
inflammatori
immunogen
effect
difficulti
control
time
dose
interfer
therefor
would
essenti
develop
improv
viral
vector
could
target
specif
cell
type
tissu
system
vivo
applic
order
minim
toxic
associ
treatment
import
safeti
issu
describ
nonvir
deliveri
strategi
wide
use
display
import
benefit
deliveri
viral
vector
notabl
potenti
lack
immunogen
low
frequenc
integr
rel
simpl
larg
scale
product
system
also
design
incorpor
varieti
nucleic
acid
easili
modifi
differ
ligand
achiev
specif
cell
type
target
target
would
allow
reduct
concentr
decreas
number
dose
need
obtain
therapeut
effect
therebi
reduc
cost
possibl
advers
effect
toxic
mention
sirna
gener
taken
mammalian
cell
includ
activ
sampl
environ
howev
certain
tissu
cell
lung
mucos
environ
eye
even
central
nervou
system
shown
effici
take
sirna
absenc
transfect
reagent
clinic
program
underway
use
direct
intravitr
inject
treatment
agerel
macular
degener
intranas
administr
pulmonari
viral
infect
differ
group
demonstr
sirna
inject
either
intravitr
subretin
monkey
rat
eye
effici
silenc
vascular
endotheli
growth
factor
vegf
express
accordingli
reduc
ocular
neovascular
base
result
antivegf
sirna
one
first
test
clinic
set
gener
advantag
local
administr
includ
fact
sirna
might
requir
simpl
formul
therefor
easier
produc
administ
addit
sitespecif
deliveri
might
facilit
local
effect
like
requir
lower
dose
sirna
carri
therapeut
function
exert
minim
system
effect
reduc
risk
ote
thu
whenev
possibl
local
deliveri
sirna
like
costeffici
strategi
vivo
conjug
lipid
may
enhanc
sirna
uptak
via
receptormedi
endocytosi
increas
membran
permeabl
otherwis
neg
charg
rna
cholesterol
coval
conjug
sirna
system
deliveri
soutscheck
cowork
studi
report
conjug
cholesterol
sens
strand
terminu
apolipoprotein
b
apob
sirna
via
pyrrolidon
linkag
cholesterolsirna
conjug
could
induc
intracellular
rnai
without
signific
loss
gene
silenc
activ
compar
unconjug
version
addit
conjug
exhibit
significantli
higher
cellular
transfer
effici
cultur
cell
without
aid
transfect
agent
signific
silenc
apob
gene
encod
protein
essenti
cholesterol
metabol
observ
liver
jejunum
intraven
administr
cholesterolsirna
conjug
vivo
silenc
apob
gene
result
decreas
plasma
apob
protein
level
consequ
reduct
total
cholesterol
level
conjug
cholesterol
also
improv
sirna
pharmacokinet
behavior
vivo
conjug
show
elimin
halflif
minut
plasma
clearanc
cl
wherea
unconjug
sirna
minut
cl
studi
also
shown
conjug
nucleic
acid
cholesterol
enhanc
cellular
uptak
human
liver
cell
without
use
transfect
reagent
vitro
good
hepat
deposit
system
administr
vivo
anoth
lipophilesirna
conjug
vitamin
e
sirna
use
system
sirna
deliveri
liver
lipophil
vitamin
e
coval
conjug
terminu
antisens
strand
sirna
partial
modifi
ribos
phosphorothio
linkag
intracellular
deliveri
sirna
process
action
dicer
gener
sirna
simultan
releas
vitamin
e
moieti
intraven
administr
conjug
achiev
signific
reduct
target
protein
apob
liver
without
induct
inflammatori
interferon
cell
penetr
peptid
cpp
also
refer
membran
permeant
peptid
mpp
protein
transduct
domain
ptd
offer
altern
tradit
method
sirna
deliveri
cpp
short
amino
acid
sequenc
abl
interact
plasma
membran
way
lead
highli
effici
uptak
cytoplasm
protein
domain
consist
mainli
posit
charg
amino
acid
arginin
lysin
respons
transloc
cpp
plasma
membran
cellular
uptak
occur
receptorindepend
fashion
energyindepend
mechan
common
featur
peptid
appear
amphipath
molecul
net
posit
charg
physiolog
ph
therefor
interact
neg
charg
head
group
plasma
membran
cppconjug
sirna
enter
differ
cell
type
high
effici
rapid
uptak
kinet
idea
use
peptid
carrier
first
suggest
year
ago
shown
transactiv
protein
tat
taken
mammalian
cell
sinc
first
report
larg
number
natur
occur
engin
cpp
discov
eg
penetratin
transportan
oligoarginin
model
amphipath
peptid
map
mpg
bipartit
amphipath
peptid
deriv
fusion
peptid
domain
protein
nuclear
local
sequenc
larg
antigen
simeoni
cowork
describ
new
peptidebas
gene
deliveri
system
first
noncoval
complex
sirna
mpg
peptid
bipartit
amphipath
peptid
deriv
fusion
peptid
domain
glycoprotein
protein
nuclear
local
signal
nl
simian
viru
larg
antigen
ratio
neg
nucleic
acid
posit
peptid
charg
decreas
luciferas
activ
found
hela
cell
investig
show
cell
entri
independ
endosom
pathway
nl
mpg
peptid
involv
electrostat
interact
nucleic
acid
nuclear
target
davidson
cowork
show
remark
strong
rnai
effect
primari
neuron
cell
use
penetratincoupl
sirna
sever
endogen
protein
observ
downregul
target
protein
peptidemedi
sirna
deliveri
found
far
effect
mediat
lipofectamin
polyethylen
glycol
peg
biocompat
hydrophil
nonion
polym
conjug
sirna
via
reduc
disulfid
linkag
pegsirna
conjug
complex
cation
polym
peptid
corecondens
agent
form
colloid
nanoparticl
call
polyelectrolyt
complex
pec
micel
neg
charg
sirna
segment
remain
complet
buri
insid
electrolyt
core
addit
coreform
polyc
result
charg
neutral
hydrophil
peg
segment
surround
charg
polyelectrolyt
core
sirna
found
pegsirna
conjug
much
stabl
nake
counterpart
incub
presenc
serum
last
hour
without
signific
loss
integr
pegsirnapolyethylenimin
pei
pec
micel
use
local
system
treatment
tumor
anim
model
sirna
target
vegf
select
antiangiogen
cancer
therapi
achiev
signific
retard
tumor
growth
mice
intraven
administr
pec
micel
vivo
initi
introduc
dna
transfect
reagent
mani
cation
liposom
test
vitro
vivo
transfect
nucleic
acid
flexibl
design
cation
lipid
structur
liposom
composit
combin
divers
method
prepar
vivo
effici
promot
notion
cation
lipid
effici
use
human
gene
transfer
nucleic
acid
includ
sirna
abl
electrostat
interact
cation
liposomeform
particl
howev
contrast
larg
dna
plasmid
molecul
consider
smaller
sirna
condens
particl
nanomer
dimens
addit
electrostat
interact
sirna
cation
liposom
pose
two
potenti
problem
rel
uncontrol
interact
process
lead
lipidsirna
complex
excess
size
poor
stabil
ii
incomplet
encapsul
sirna
molecul
therebi
expos
sirna
potenti
enzymat
physic
degrad
sever
liposom
system
develop
year
zhang
colleagu
success
deliv
sirna
lung
tumor
cell
load
sirna
liposom
bear
arginin
octam
attach
liposom
surfac
liposom
contain
sirna
show
high
stabil
protect
incorpor
sirna
achiev
high
transfect
effici
lung
tumor
cell
anoth
new
liposom
system
abl
deliv
sirna
differ
cell
line
hela
human
umbil
vein
endotheli
cell
huvec
low
concentr
sirnacontain
liposom
abl
silenc
protein
kinas
express
concentrationdepend
manner
improv
cellular
uptak
sirna
escap
endosomallysosom
pathway
anoth
exampl
liposom
use
deliveri
stabl
nucleic
acid
lipid
particl
snalp
vivo
mous
model
hepat
b
viru
hbv
infect
stabil
sirna
incorpor
special
liposom
form
snalp
longer
plasma
liver
compar
unformul
sirna
inject
mice
associ
reduct
serum
hbv
dna
effect
dosedepend
persist
week
dose
likewis
treatment
guinea
pig
pool
snalpformul
sirna
target
polymeras
l
gene
zair
speci
ebola
viru
ebov
complet
protect
anim
death
administ
shortli
ebov
challeng
dendrim
consist
central
core
molecul
multipl
arm
branch
polym
project
core
molecul
refer
gener
success
repeat
unit
along
branch
form
next
gener
ie
gener
gener
termin
gener
success
branch
creat
use
stepwis
synthesi
allow
particl
size
precis
control
step
branch
synthesi
number
branch
increas
exponenti
caus
increas
polym
densiti
pattern
creat
physic
protect
void
within
macromolecul
chemic
properti
differ
surfac
exploit
host
nucleic
acid
well
studi
molecul
base
ethylen
diamin
ammonia
core
polyamidoamin
pamam
dendrit
base
butylenediamid
core
polypropylenemin
dendrit
solubl
pamam
dendrim
enhanc
partial
acetyl
reactiv
amino
group
conjug
variou
target
entiti
folic
acid
target
receptor
specif
cancer
cell
although
pamam
dendrim
larg
appli
deliveri
plasmid
odn
studi
report
use
monoclon
antibodytarget
dendrim
target
specif
cell
latter
strategi
yet
shown
effect
sirna
deliveri
kang
cowork
report
use
pamam
dendrim
deliveri
sirna
target
multidrug
resist
protein
mdr
cell
strategi
effect
pei
differ
molecular
weight
degre
branch
modif
larg
use
tranfect
sirna
differ
cell
line
anim
model
pei
consist
linear
branch
alkyl
chain
interspers
amin
dens
cation
natur
pure
pei
caus
polym
cytotox
linear
pei
usual
show
higher
transfect
effici
lower
cytotox
branch
pei
grzelinski
colleagu
show
complex
unmodifi
sirna
pei
lead
format
structur
condens
around
complet
cover
sirna
investig
report
deliveri
sirna
growth
factor
pleiotropin
complex
pei
abl
gener
antitumor
effect
ortothop
mous
glioblastoma
model
cell
grow
intracrani
urbanklein
cowork
show
noncoval
complex
synthet
sirna
lowmolecularweight
pei
effici
stabil
sirna
deliv
cell
display
full
bioactiv
nontox
concentr
pei
polym
complex
molecul
peg
peptid
contribut
pei
complex
stabil
kim
collabor
conjug
prostat
cancerbind
peptid
pei
via
peg
linker
deliv
vegf
small
interf
molecul
human
prostat
carcinoma
pc
cell
report
enhanc
genesilenc
activ
maintain
even
serum
condit
anoth
exampl
antivegf
sirnapeihyaluron
acid
ha
achiev
inhibit
tumor
growth
use
ha
receptormedi
endocytosi
tumor
cell
vivo
complex
success
appli
specif
antiangiogen
therapeut
treatment
diseas
tissu
ha
receptor
liver
kidney
linear
polypeptid
pll
abl
effect
complex
nucleic
acid
use
mani
posit
charg
amino
group
form
stabl
polyplex
pll
alon
highli
cytotox
charg
shield
pll
peg
mitig
toxic
make
use
vivo
therapeut
genedeliveri
agent
pei
polym
pll
complex
molecul
part
micel
atcol
first
biomateri
introduc
gene
deliveri
system
gener
pepsin
treatment
type
collagen
calf
dermi
remov
telopeptid
immunogen
n
c
termin
end
reduc
immunogen
size
complex
form
atcol
neg
charg
nucleic
acid
molecul
determin
ratio
two
compon
complex
atcol
shown
protect
sirna
allow
vivo
deliveri
intratumor
inject
atcolsirna
complex
target
growth
factor
vegf
perform
prostat
carcinoma
xenograft
model
result
decreas
tumor
growth
angiogenesi
suppress
tumor
growth
also
observ
upon
downregul
proteinaseactiv
pancreat
carcinoma
xenograft
cervic
xenograft
addit
atcolmedi
local
system
applic
sirna
target
myostatin
neg
regul
skelet
muscl
growth
caus
mark
increas
muscl
mass
within
week
applic
skelet
muscl
normal
diseas
mice
impli
atcolmedi
applic
sirna
could
power
tool
treat
diseas
muscular
atrophi
gelatin
consist
denatur
collagen
shown
great
promis
vitro
vivo
deliveri
vehicl
cation
gelatin
nanoparticl
rel
simpl
produc
compar
synthet
polym
shown
display
transfect
effici
vitro
approxim
one
order
magnitud
less
pei
show
less
cytotox
well
cation
gelatin
use
mediat
vectorbas
rnai
murin
model
obstruct
nephropathi
intraureter
deliveri
administr
plasmid
encod
sirna
transform
growth
receptor
gene
result
reduct
collagen
content
fibrot
tissu
kidney
interstitium
day
administr
gelatin
proven
effect
mediat
dna
vectorbas
rnai
squamou
cell
carcinoma
murin
xenograft
model
vector
encod
sirna
vegf
complex
cation
gelatin
microspher
administ
vivo
show
effect
knockdown
suppress
tumor
growth
reduc
vascular
chitosan
posit
charg
natur
biodegrad
polym
show
high
biocompat
low
toxic
immunogen
obtain
deacetyl
chitin
result
biodegrad
polysaccharid
compos
two
subunit
dglucosamin
nacetyldglucosamin
physicochem
properti
target
efficaci
chitosansirna
nanoparticl
depend
molecular
weight
degre
deacetyl
chitosan
howard
colleagu
show
chitosansirna
particl
led
enhanc
green
fluoresc
protein
egfp
knockdown
bronchiol
epitheli
cell
transgen
mice
nasal
administr
complex
tan
collabor
gener
chitosan
nanoparticl
encapsul
fluoresc
quantum
dot
deliv
human
epiderm
growth
factor
neu
sirna
target
deliveri
sirna
overexpress
cancer
cell
shown
specif
chitosanquantum
dot
particl
surfacelabel
antibodi
cyclodextrin
cyclic
oligom
glucos
amphipath
structur
central
hydrophob
caviti
hydrophil
exterior
make
water
solubl
cyclic
oligom
use
carrier
small
organ
molecul
display
high
biocompat
low
toxic
cyclodextrincontain
polyc
cdp
function
transferrin
achiev
preferenti
uptak
transferrin
receptorexpress
tumor
cell
employ
murin
model
ewe
sarcoma
target
ewe
sarcomafriend
leukemia
viru
integr
gene
product
similarli
tumor
growth
reduct
tumor
xenograft
report
target
ribonucleotid
reductas
subunit
nontarget
nanoparticl
significantli
less
effici
upon
intraven
inject
compar
funtion
counterpart
recent
publish
result
shown
first
target
deliveri
synthet
sirna
human
via
selfassembl
cyclodextrinbas
nanoparticl
studi
report
target
vivo
deliveri
sirna
reduc
prolif
activ
broad
spectrum
human
mous
rat
monkey
cancer
type
anoth
target
nanoparticl
formul
addit
specif
sirna
contain
cdp
peg
steric
stabil
agent
transferrin
fourcompon
formul
selfassembl
nanoparticl
administ
intraven
patient
nanoparticl
circul
local
tumor
cdp
contain
organ
group
proton
around
ph
chemicalsens
mechan
trigger
number
process
escap
mechan
endocyt
vesicl
releas
nucleic
acid
cytoplasm
compon
formul
small
enough
clear
bodi
via
kidney
nanoparticl
disassembl
individu
part
use
treat
first
patient
phase
clinic
trial
may
trial
safeti
studi
treat
adult
solid
tumor
refractori
standardofcar
therapi
import
consider
take
account
therapeut
applic
rnai
dosag
sirna
need
achiev
effici
silenc
import
disadvantag
system
deliveri
system
larg
amount
sirna
need
administr
achiev
effici
vivo
gene
silenc
target
site
therefor
strategi
would
facilit
celltypespecif
deliveri
could
allow
reduct
amount
sirna
need
andor
number
dose
administ
select
ligand
bind
cellspecif
receptor
express
target
cell
conjug
polym
cation
lipid
order
promot
specif
cell
uptak
via
receptormedi
endocytosi
ligandtarget
deliveri
accomplish
direct
attach
ligand
sirna
moieti
incorpor
sirna
complex
formul
sever
group
exploit
specif
deliveri
strategi
schiffel
collabor
develop
tumorselect
deliveri
system
sirna
complex
pegyl
pei
arginineglycineaspart
acid
rgd
peptid
attach
distal
end
peg
target
integrin
express
tumor
neovasculatur
pegpeirgd
system
use
deliv
sirna
inhibit
vegf
receptor
improv
serum
stabil
compar
unformul
sirna
altern
kim
cowork
develop
approach
sirna
silenc
green
fluoresc
protein
gfp
complex
peipeg
nanoparticl
function
folat
nanoparticl
effici
target
gfptransfect
human
epiderm
carcinoma
cell
overexpress
folat
receptor
abund
mani
cancer
frequent
use
target
drug
deliveri
mannos
receptor
mannoserel
receptor
highli
express
dendrit
cell
use
target
cell
transferrin
receptor
typic
upregul
cancer
cell
also
use
target
sirnacyclodextrincontain
polyc
transferrin
receptorexpress
tumor
cell
lung
gastric
cancer
ewe
sarcoma
altern
aptamersirna
chimer
rna
shown
capabl
celltypespecif
bind
deliveri
mcnamara
cowork
use
aptam
prostatespecif
membran
antigen
psma
cell
surfac
receptor
overexpress
prostat
cancer
cell
tumor
vascular
endothelium
downregul
pololik
kinas
bcell
xenograft
model
prostat
cancer
induc
tumor
growth
inhibit
tumor
regress
sinc
first
report
rnaimedi
inhibit
respiratori
syncyti
viru
rsv
sever
vivo
proofofconcept
studi
shown
technolog
like
viabl
therapeut
altern
futur
limit
current
therapi
mani
viral
infect
avail
genom
sequenc
mani
pathogen
virus
open
field
novel
rnaibas
antivir
therapi
viral
gene
essenti
viru
replic
host
gene
essenti
viru
entri
play
essenti
role
viru
life
cycl
constitut
attract
target
silenc
gene
relev
viral
infect
hiv
hepat
sever
acut
respiratori
syndrom
sar
associ
coronaviru
achiev
use
rnai
hiv
perfect
exampl
viru
immedi
intervent
need
although
signific
success
achiev
current
antivir
therapi
toxic
complex
cost
mostli
appear
drug
resist
call
novel
method
intervent
previous
shown
silenc
primari
hiv
receptor
chemokin
cc
motif
receptor
use
sirna
result
prevent
viral
entri
human
peripher
blood
lymphocyt
primari
hematopoiet
cell
sinc
hiv
viral
transcript
effect
target
use
rnai
howev
target
singl
sequenc
might
hamper
viral
escap
mechan
way
fail
monotherapi
altern
strategi
develop
avoid
genet
variabl
hiv
lead
decreas
therapeut
effect
rnaibas
agent
sever
versatil
strategi
involv
multipl
rnai
effector
gene
express
inhibitor
call
combinatori
rnai
cornai
suggest
eg
target
singl
region
viral
dna
multipl
shrna
express
individu
promot
concatem
one
promot
strategi
target
sever
region
viral
dna
viral
host
cellular
dna
construct
express
multipl
shrna
one
separ
promot
express
long
hairpin
rna
one
promot
silenc
numer
region
singl
target
use
cornai
vector
coexpress
shrna
nucleic
acidbas
inhibitor
aptam
ribozym
transact
respons
element
tar
decoy
therapeut
protein
exampl
kind
therapeut
strategi
benitec
rnaibas
antihiv
candid
product
mediat
dnadirect
rnai
ddrnai
use
lentivir
vector
contain
three
gene
shrna
target
tatrev
exon
hi
ribozym
nucleolarloc
tar
decoy
therapi
deliv
mobil
hematopoiet
stem
cell
stem
cell
circul
peripher
collect
isol
genet
modifi
lentivir
vector
express
therapeut
product
patient
undergo
full
chemoabl
regen
cell
bone
marrow
lymphoma
cell
kill
treat
stem
cell
infus
back
bloodstream
hepat
b
c
viru
infect
progress
chronic
liver
diseas
infect
show
poor
respons
current
therapi
affect
patient
eventu
develop
cirrhosi
requir
liver
transplant
develop
liver
cancer
hepat
c
sirna
silenc
led
reduct
detect
viru
infect
cell
studi
shown
silenc
surfac
antigen
region
hepat
b
viru
use
sirna
viral
transcript
viral
antigen
viral
genom
dna
significantli
reduc
vivo
anoth
exampl
viral
diseas
could
tackl
rnaibas
therapi
influenza
infect
new
therapi
infect
requir
everi
year
virus
chang
viral
determin
give
rise
new
virul
strain
influenza
viru
genom
contain
eight
piec
segment
negativesens
rna
code
total
protein
hemagglutinin
ha
neuroaminidas
na
nucleoprotein
np
pa
separ
genom
segment
viral
rna
allow
reassort
viral
rna
one
type
influenza
viru
infect
cell
result
rapid
chang
viral
genet
produc
antigen
shift
chang
allow
viru
infect
new
host
speci
us
center
diseas
control
prevent
express
major
concern
potenti
viru
mutat
respons
global
pandem
human
current
vaccin
exist
antivir
agent
may
protect
newli
emerg
strain
influenza
addit
flu
vaccin
manufactur
use
chicken
eggbas
system
return
low
yield
amen
scale
would
inadequ
fight
pandem
flu
despit
high
mutat
recombin
rate
new
chemic
synthes
easili
scalabl
rnaibas
drug
could
design
multipl
specif
sirna
target
conserv
region
requir
viral
replic
could
use
antivir
activ
across
multipl
strain
flu
sever
pharmaceut
compani
alnylam
pharmaceut
novarti
collabor
develop
rnaibas
drug
target
pandem
influenza
infect
rsv
ubiquit
environ
common
caus
bronchiolitisassoci
hospit
children
immunocompromis
adult
monick
cowork
show
activ
extracellular
signalregul
kinas
erk
via
epiderm
growth
factor
receptor
egfr
occur
rsv
infect
lead
pronounc
inflamm
prolong
surviv
infect
cell
target
egfr
specif
sirna
result
apoptosi
resolut
inflamm
addit
kong
colleagu
show
mice
intranas
treat
sirna
nanoparticl
target
viral
gene
infect
rsv
show
substanti
decreas
viru
titer
lung
decreas
inflamm
airway
reactiv
rel
control
similarli
mani
viral
infect
tackl
use
rnaibas
approach
possibl
induc
apoptosi
primari
patient
tumor
sampl
target
gene
human
papillomaviru
case
sar
recent
shown
sarsassoci
corona
viru
replic
effici
inhibit
use
sirna
two
viral
polymeras
remark
exampl
pathogen
respons
import
human
diseas
mortal
flavivirus
includ
dengu
viru
japanes
enceph
viru
yellow
fever
viru
west
nile
viru
current
specif
therapi
avail
flaviviru
infect
commerci
vaccin
three
flavivirus
evid
support
idea
rnai
success
use
combat
viral
diseas
contrast
virus
bacteria
gener
amen
silenc
sirna
replic
mostli
outsid
host
cell
howev
might
still
possibl
reduc
morbid
mortal
lifethreaten
bacteri
infect
silenc
host
gene
involv
aspect
immun
respons
lead
advers
consequ
exampl
reduc
express
proinflammatori
cytokin
tumor
necrosi
lessen
septic
shock
mice
treat
lipopolysacharid
without
jeopard
develop
protect
immun
similarli
silenc
host
gene
involv
mediat
bacteri
invas
constitut
interest
approach
eg
silenc
murin
lung
epitheli
cell
inhibit
invas
pseudomona
aeruginosa
major
pulmonari
pathogen
cystic
fibrosi
patient
lipid
raftdepend
mechan
mycobacteri
infect
difficult
treat
characterist
extrem
hard
cell
wall
natur
resist
antibacteri
work
destroy
cell
wall
moreov
pathogen
elud
steril
immun
resid
intracellular
compart
host
cell
protect
microbicid
attack
therefor
mycobacteri
infect
tuberculosi
perfect
candid
treatment
rnaibas
therapeut
target
host
gene
involv
mycobacteri
invas
growth
insid
cell
feasibl
use
antisens
therapi
treat
mycobacterium
tuberculosi
infect
proven
studi
phosphorothioatemodifi
antisens
oligodeoxyribonucleotid
glutamin
synthetas
transcript
use
enzym
associ
mycobacteri
pathogen
format
polylglutamateglutamin
cell
wall
structur
therefor
reduc
activ
enzym
would
great
impact
bacteri
replic
one
recent
studi
also
show
inhibit
mycobacteri
growth
reduct
lysosom
enzym
peptidoglycan
hydrolas
facilit
mycobacterialinduc
secret
lysosom
macrophag
plasma
membran
protozoan
parasit
caus
diseas
consider
medic
veterinari
import
throughout
africa
asia
america
first
report
rnai
protozoan
parasit
made
elisabetta
ullu
laboratori
investig
found
dsrna
could
induc
sequencespecif
mrna
degrad
trypanosoma
brucei
sinc
rnai
provid
invalu
tool
studi
brucei
biolog
addit
test
therapeut
tool
brucei
infect
vivo
similar
manner
congolens
caus
agent
nagana
diseas
cattl
also
shown
possess
rnai
machineri
widespread
resist
common
antimalari
drug
show
need
efficaci
innov
drug
vaccin
fight
plasmodium
parasit
latter
part
centuri
alarm
increas
number
case
malaria
report
indian
subcontin
southeast
asia
south
america
chloroquin
remain
gold
standard
treatment
malaria
today
howev
chloroquin
resist
grow
concern
caus
agent
diseas
plasmodium
falciparum
member
intracellular
protozoan
phylum
apicomplexa
rnalik
silenc
report
plasmodium
parasit
remain
controversi
whether
phenomenon
actual
take
place
organ
kumar
cowork
silenc
serinethreonin
protein
parasit
show
enzym
play
essenti
role
life
cycl
therefor
offer
potenti
target
drug
develop
downsid
approach
highli
conserv
throughout
evolut
therefor
toxic
side
effect
expect
unless
specif
variant
protein
identifi
anoth
protozoan
parasit
entamoeba
histolytica
caus
human
amebiasi
insid
host
parasit
invad
intestin
mucosa
caus
dysenteri
travel
circulatori
system
liver
caus
develop
abscess
vayssi
colleagu
achiev
specif
effici
silenc
mrna
result
loss
parasit
highli
organ
microtubul
array
result
show
essenti
microtubul
nucleat
cycl
parasit
importantli
protein
primari
amino
acid
sequenc
homolog
ident
human
homolog
therefor
specif
sirna
may
develop
destroy
parasit
leav
host
counterpart
untouch
larg
number
exon
mutat
result
aberr
splice
document
could
good
target
sirnabas
therapi
strike
exampl
detriment
effect
mutat
exon
splice
signal
nucleotid
substitut
massiv
million
base
pair
dystrophin
gene
duchenn
muscular
dystrophi
dmd
sever
progress
neuromuscular
disord
caus
sever
differ
mutat
usual
lossoffunct
mutat
dmd
mutat
genom
delet
larg
number
exon
intron
point
mutat
caus
diseas
aberr
splice
abolish
product
function
protein
dystrophin
posit
cytoplasm
side
skelet
muscl
sarcolemma
commun
signal
extracellular
matrix
cellular
contractil
apparatu
stabil
cell
membran
particularli
reveal
substitut
exon
creat
prematur
termin
codon
also
introduc
exon
splice
silenc
bind
heterogen
nuclear
ribonucleoprotein
result
partial
skip
interestingli
mrna
code
one
spectrinlik
repeat
retain
correct
read
frame
produc
partial
function
protein
explain
individu
harbor
mutat
milder
form
diseas
recent
studi
show
novel
strategi
treatment
patholog
employ
steric
block
methylphosphorothio
antisens
oligoribonucleotid
morpholino
oligom
conjug
dendrimer
octoguanidin
vivomorpholino
studi
show
local
administr
specif
dystroph
mous
model
bear
nonsens
mutat
vivomorpholino
system
deliveri
respect
effect
skip
mutat
exon
dystrophin
gene
creat
shorter
infram
transcript
translat
lead
nearnorm
dystrophin
express
skelet
cardiac
muscl
sirna
therapeut
approach
appli
number
context
includ
dominantli
inherit
untreat
singlebas
mutat
lead
neurodegen
diseas
alzheim
diseas
ad
recent
studi
miller
et
al
amyloid
precursor
protein
app
tau
gene
chosen
candid
rnai
target
central
role
inherit
acquir
form
agerel
dementia
ad
character
two
major
patholog
hallmark
senil
plaqu
contain
deriv
cleavag
app
neurofibrillari
tangl
contain
filament
tau
protein
well
known
product
play
essenti
role
pathogenesi
form
ad
sporad
inherit
form
mutat
three
gene
known
caus
famili
ad
gene
encod
app
presenilin
presenilin
act
dominantli
enhanc
product
neurotox
best
studi
ad
mutat
well
character
mutat
microtubuleassoci
protein
tau
mapt
gene
swedish
doubl
mutat
appsw
two
consecut
missens
chang
alter
adjac
amino
acid
near
cleavag
site
use
target
model
design
allelespecif
sirna
sirna
display
success
optim
allelespecif
silenc
mutant
tau
app
allel
singlenucleotid
app
substitut
follow
amino
acid
substitut
success
target
forkedsirna
fsirna
approach
show
high
allelespecif
gene
silenc
mutat
within
downstream
altern
splice
exon
mapt
gene
encod
tau
protein
disrupt
ratio
mrna
includ
exclud
exon
also
found
exon
encod
fourth
four
repeat
microtubulebind
domain
r
disrupt
balanc
four
repeat
microtubul
bind
domain
three
repeat
microtubul
bind
domain
isoform
result
hyperphosphoryl
aggreg
tau
protein
neurofibrillari
tangl
hallmark
sever
neurodegen
diseas
ad
numer
mutat
within
around
mapt
exon
disrupt
exon
intron
splice
element
caus
inherit
neuropatholog
disord
frontotempor
dementia
parkinson
link
chromosom
demonstr
direct
relationship
aberr
express
due
altern
splice
disrupt
neuropatholog
miller
collabor
success
target
four
missens
tau
mutat
respons
employ
seri
nucleotid
sirna
design
mapt
mutat
result
demonstr
sirna
engin
silenc
express
diseas
allel
differ
wildtyp
allel
littl
singl
nucleotid
dominantli
inherit
untreat
neurodegen
diseas
polyglutamin
poli
q
neurodegener
machadojoseph
diseas
spinocerebellar
ataxia
type
poli
q
neurodegen
disord
consist
least
nine
diseas
caus
cagrepeat
expans
encod
poli
q
diseas
protein
poli
q
expans
confer
domin
toxic
properti
mutant
protein
associ
aberr
accumul
diseas
protein
neuron
select
inactiv
mutant
allel
miller
cowork
took
advantag
singl
nucleotid
polymorph
snp
gene
g
c
transit
immedi
cag
repeat
snp
linkag
disequilibrium
diseasecaus
expans
famili
segreg
perfectli
diseas
allel
worldwid
diseas
chromosom
carri
c
variant
optim
differenti
suppress
sirna
contain
central
place
mismatch
design
central
mismatch
might
discrimin
wild
type
mutant
allel
design
sirna
place
c
snp
posit
preced
final
three
triplet
cag
repeat
caus
allelespecif
suppress
mutant
protein
rnai
approach
show
promis
treatment
sever
neurodegen
diseas
includ
huntington
diseas
spinocerebellar
ataxia
amyotroph
later
sclerosi
al
anoth
snpassoci
patholog
sickl
cell
anemia
patholog
inherit
blood
diseas
caus
singl
nucleotid
mutat
human
hbb
gene
codon
glu
val
creat
hemoglobin
variant
polymer
upon
deoxygen
produc
long
fiber
distort
red
blood
cell
shape
lead
reduct
red
blood
cell
flexibl
impair
transit
microvasculatur
individu
homozyg
mutant
allel
hbb
sever
clinic
symptom
abnorm
hemoglobin
produc
gene
term
sickl
cell
hemoglobin
polymer
low
oxygen
tension
chang
red
blood
cell
rheolog
shape
potenti
result
vasoocclus
crisi
infarct
organ
damag
signific
reduct
mous
adult
mrna
sirna
report
murin
erythroleukemia
cell
sever
tumorigen
process
emerg
result
molecular
alter
point
mutat
transloc
lead
gener
novel
chimer
fusion
protein
protein
consequ
infram
join
two
gene
gener
uniqu
fusion
protein
novel
function
mixedlineag
leukaemia
mll
famili
oncogen
fusion
protein
repres
one
class
deregul
transcript
regul
acut
leukemia
exampl
fusion
protein
ewe
sarcoma
ewswilm
tumor
small
round
cell
desmoplast
tumor
ewsactiv
transcript
factor
clear
cell
sarcoma
ewsmyxoid
chrondrosarcoma
chn
extraskelet
myxoid
chondrosarcoma
fuschop
round
cell
myxoid
liposarcoma
fusion
protein
could
excel
address
target
rnaibas
therapi
present
cancer
cell
normal
tissu
sirna
could
directli
design
junction
point
fusion
protein
transcript
inhibit
synthesi
fusion
protein
sever
group
appli
rnai
technolog
vitro
vivo
new
approach
treatment
type
cancer
junction
oncogen
mirna
short
nonprotein
code
rna
nucleotid
length
known
alter
gene
express
posttranscript
level
integr
compon
genet
program
account
approxim
predict
transcript
plant
worm
vertebr
gene
local
intron
proteincod
gene
noncod
region
genom
interest
role
mirna
regul
fundament
biolog
process
emerg
rapidli
follow
discoveri
first
mirna
c
elegan
decad
ago
distinct
class
mirna
identifi
key
regul
gene
activ
suppress
highli
specif
differ
tissu
development
stage
function
appreci
fundament
biolog
process
cellular
function
cell
prolifer
stem
cell
divis
cell
differenti
stress
respons
apoptosi
immun
transcript
regul
mirna
sequenc
freeli
avail
web
interfac
http
micrornasangeracuk
actual
uniqu
precursor
matur
mirna
identifi
tabul
last
mirna
base
registri
releas
includ
primat
rodent
bird
fish
worm
fli
plant
virus
given
remark
spectrum
biolog
pathway
regul
least
part
mirna
surpris
abnorm
mirna
signatur
identifi
diseas
state
may
valuabl
diagnost
andor
prognost
marker
diseas
furthermor
modul
activ
may
therapeut
benefit
recent
use
synthet
analog
small
rna
molecul
term
antagomir
shown
gene
interest
specif
target
multipl
step
mirna
process
pathway
could
target
achiev
inhibit
mirna
product
function
target
degrad
primirna
transcript
nucleu
rnase
hbase
antisens
oligonucleotid
aso
may
feasibl
could
constitut
interest
approach
inhibit
product
multipl
mirna
polycistron
primirna
transcript
rnase
h
recogn
rnadna
duplex
cleav
rna
strand
sirna
target
primirna
like
effect
sirna
load
risc
work
primarili
cytoplasm
primirna
substrat
inaccess
altern
target
loop
hairpin
rnaas
h
aso
sirna
may
possibl
inde
sever
investig
develop
chemic
engin
singl
doublestrand
oligonucleotid
specif
silenc
mirna
express
krutzfeldt
cowork
design
cholesterolconjug
singlestrand
rna
molecul
nucleotid
complementari
matur
mirna
specif
silenc
liver
lung
intestin
heart
skin
bone
marrow
week
singl
intraven
inject
result
downregul
hundr
gene
regul
mirna
achiev
davi
colleagu
extend
studi
highlight
inhibit
mirna
may
possibl
therapeut
approach
treatment
diseas
report
inhibit
normal
highfatf
mice
phosphorothio
modifi
antisens
oligonucleotid
week
signific
reduct
hepat
sterol
fattyacid
synthesi
rate
stimul
hepat
fattyacid
oxid
observ
result
suggest
key
regul
cholesterol
fattyacid
metabol
could
therapeut
target
metabol
cardiovascular
diseas
addit
contribut
liver
trophism
hepat
c
viru
hcv
acceler
bind
ribosom
viral
rna
therebi
stimul
hcv
translat
involv
hcv
infect
reveal
viral
factor
potenti
target
rnai
mirnabas
antivir
strategi
possibl
import
novel
therapi
hcv
infect
sever
pharmaceut
compani
regulu
therapeut
santari
pharma
develop
portfolio
built
mirna
biolog
differ
mirna
target
evid
new
kind
therapeut
field
emerg
prior
discoveri
rnai
nucleic
acidbas
antisens
technolog
sequencespecif
inhibit
gene
express
use
number
year
antisensebas
approach
present
great
advantag
allow
gene
silenc
virtual
target
high
select
specif
watsoncrick
base
pair
complet
human
genom
project
identif
approxim
gene
human
dna
possibl
therapeut
intervent
becam
enorm
theoret
diseaseassoci
gene
amen
antisensemedi
suppress
compar
antisens
strategi
howev
antisens
dna
oligonucleotid
ribozym
rnai
consider
potent
mean
may
function
much
lower
concentr
fact
may
requir
molecul
dsrna
caus
gene
silenc
addit
potenc
chemic
modifi
sirna
mirna
may
even
higher
broad
implic
clinic
set
would
mean
less
frequent
andor
lower
dose
increas
patient
complianc
decreas
risk
advers
effect
sirna
also
natur
cellular
compon
mean
cell
capac
handl
breakdown
product
thu
reduc
toxic
develop
sirnabas
drug
also
requir
shorter
pharmacolog
develop
convent
drug
vs
year
sinc
proof
concept
sirna
compound
made
strand
rna
manufactur
rna
synthes
greatli
facilit
largescal
product
produc
chemic
synthesi
process
fall
categori
biolog
sever
import
advantag
regulatori
point
view
hand
deliveri
sirna
technic
difficult
achiev
although
advanc
made
area
much
work
still
remain
done
full
therapeut
potenti
applic
fulli
exploit
clinic
intervent
program
rnai
limit
use
treat
patholog
caus
express
overexpress
given
protein
presenc
exogen
organ
mechan
work
suppress
protein
express
ie
rnai
confer
therapeut
advantag
situat
amelior
diseas
achiev
lossoffunct
furthermor
even
though
gene
target
could
potenti
silenc
use
rnai
practic
gene
harder
target
other
newli
design
algorithm
need
develop
order
address
issu
final
offtarget
effect
sirna
target
unwant
gene
could
lead
safeti
issu
clinic
situat
differ
strategi
gene
express
inhibit
use
mani
therapeut
applic
among
treatment
ocular
diseas
inde
intraocular
deliveri
nucleic
acid
attract
much
interest
recent
year
first
antisens
drug
achiev
market
clearanc
fomivirsen
develop
isi
pharmaceut
carlsbad
ca
usa
drug
approv
treatment
cytomegaloviru
cmv
retin
patient
aid
left
untreat
lead
blind
worldwid
commerci
right
licens
novarti
ophthalm
formerli
cibavis
fomivirsen
nucleotid
long
block
translat
viral
mrna
bind
code
segment
key
cmv
gene
administ
intraocular
inject
antisensemedi
reduct
cmv
protein
limit
viral
replic
inhibit
adsorpt
cmv
host
cell
possibl
interact
virion
may
prevent
adsorpt
uncoat
approv
import
antisens
technolog
demonstr
antisens
drug
effect
treatment
local
diseas
could
gain
market
approv
regulatori
agenc
around
world
antisens
drug
could
manufactur
commerci
use
although
drug
chang
cours
diseas
hardli
consid
commerci
success
offer
limit
basi
sale
extrem
small
number
hivinfect
individu
cmv
retin
declin
appear
new
antihiv
drug
particularli
proteas
inhibitor
combin
treatment
regimen
addit
fomivirsen
shown
induc
ocular
inflamm
one
major
advers
effect
first
sirna
drug
bevasiranib
opko
health
miami
fl
usa
formerli
acuiti
pharmaceut
sirna
shut
gene
produc
vegf
stimul
blood
vessel
overgrowth
regul
blood
vessel
permeabl
phase
ii
studi
demonstr
safeti
product
singl
dose
bevasiranib
safe
significantli
reduc
neovascular
vessel
leakag
dosedepend
manner
week
patient
wet
agerel
macular
degener
amd
recent
opko
health
decid
termin
phase
iii
trial
bevasiranib
treatment
wet
amd
follow
review
preliminari
trial
data
show
although
bevasiranib
show
activ
use
conjunct
ranibizumab
trial
unlik
meet
primari
endpoint
allergan
irvin
ca
usa
formerli
sirna
therapeuticsmerck
chemic
modifi
sirna
vegf
found
primarili
vascular
endotheli
cell
stimul
vegf
placent
growth
factor
pgf
result
growth
new
blood
vessel
target
design
shut
activ
patholog
angiogenesi
initi
vegf
pgf
show
promis
result
phase
studi
evalu
safeti
toler
biolog
effect
singleascend
dose
patient
amd
allergan
recent
halt
develop
drug
fail
meet
key
efficaci
endpoint
phase
ii
studi
although
initi
held
promis
second
rnai
drug
enter
human
test
allergan
decis
shelv
drug
entir
unexpect
light
recent
report
immunostimulatori
natur
sirna
jayakrishna
ambati
group
show
sirna
least
nucleotid
length
includ
bevasiranib
suppress
neovascular
mous
model
choroid
dermal
neovascular
regardless
sequenc
target
trigger
howev
even
bevasiranib
proven
effect
clinic
drug
expect
face
difficulti
attempt
share
amd
market
ranibizumab
given
strong
safeti
efficaci
record
latter
inde
alnylam
pharmaceut
develop
vegftarget
sirna
drug
fall
compani
drop
program
light
grow
competit
decid
focu
effort
rsv
despit
loss
three
drug
candid
amd
appear
target
rather
indic
may
main
issu
real
valu
sirna
tackl
target
access
antibodi
small
molecul
aim
vegf
lose
real
benefit
sirna
approach
meanwhil
quark
pharmaceut
continu
move
forward
rnaibas
amd
treatment
synthet
sirna
molecul
design
inhibit
express
quark
pharmaceut
proprietari
target
product
candid
licens
pfizer
exclus
worldwid
basi
result
phase
iii
trial
show
well
toler
patient
wet
amd
follow
success
complet
phase
clinic
studi
current
two
phase
ii
studi
diabet
macular
degener
amd
lung
also
prime
target
rnaibas
therapeut
inhal
drug
reach
respiratori
system
directli
alnylam
pharmaceut
develop
nasal
formul
aim
treatment
rsv
infect
rsv
highli
contagi
caus
infect
upper
lower
respiratori
tract
infect
typic
result
coldlik
symptom
lead
seriou
respiratori
ill
extrem
case
death
design
target
nucleocapsid
n
gene
rsv
genom
gene
requir
rsv
replic
therebi
reduc
viru
abil
reproduc
earli
alnylam
pharmaceut
inc
present
data
phase
ii
gemini
studi
show
statist
signific
decreas
infect
rate
adult
experiment
infect
rsv
demonstr
antivir
activ
diseas
set
ongo
expand
phase
ii
clinic
trial
aim
extend
understand
safeti
toler
antivir
activ
natur
infect
patient
acut
renal
failur
arf
also
known
acut
kidney
injuri
aki
rapid
loss
renal
function
due
damag
kidney
lead
death
current
effect
therapi
phase
ii
clinic
trial
underway
evalu
efficaci
treatment
arf
develop
quark
pharmaceut
fremont
ca
usa
target
tumor
protein
gene
thu
delay
apoptosi
damag
kidney
tubular
cell
enabl
activ
natur
repair
mechan
therefor
rnaimedi
therapeut
mention
includ
tabl
current
test
treatment
sever
diseas
relat
aberr
express
gene
express
addit
pharmaceut
compani
summar
tabl
ii
develop
preclin
program
use
rnaibas
compound
treat
wide
rang
diseas
rnai
program
care
move
forward
rnaibas
therapi
establish
novel
class
therapeut
intervent
sever
challeng
need
address
sirnabas
therapi
wide
use
eg
sirna
design
improv
sirna
stabil
develop
good
deliveri
system
unmodifi
nake
sirna
rapidli
degrad
endo
exonucleas
result
short
halfliv
vivo
discuss
section
chemic
modif
introduc
rna
structur
enhanc
biolog
stabil
without
advers
affect
genesilenc
activ
howev
good
deliveri
system
consid
mani
import
remain
hurdl
widespread
therapeut
use
rnaibas
compound
select
formul
sirna
appropri
biocompat
genocompat
deliveri
system
necessari
improv
biolog
stabil
target
cell
uptak
pharmacokinet
sirna
organ
deliveri
drug
target
import
efficaci
drug
failur
reach
target
mean
failur
provid
therapeut
effect
multifunct
deliveri
system
must
implement
accomplish
mani
task
right
place
right
time
integr
numer
function
deliveri
system
success
improv
therapeut
efficaci
sirnabas
drug
differ
design
criteria
must
consid
complet
deliveri
system
must
adapt
mean
abl
modifi
respons
new
mechanist
inform
yield
bioactiv
molecul
easili
modifi
surfac
well
defin
structur
control
size
therebi
ensur
reproduc
pharmacokinet
pharmacodynam
good
deliveri
system
also
facilit
enhanc
penetr
retent
sirna
specif
cell
andor
tissu
deliveri
formul
compon
must
scalabl
current
good
manufactur
practic
cgmp
condit
facilit
largescal
product
would
also
necessari
develop
nonimmunostimulatori
formul
would
enabl
repeat
dose
necessari
formul
addit
allow
complet
sirna
encapsul
protect
nucleas
recognit
tlr
cell
surfac
moreov
system
compon
nontox
size
would
allow
clear
via
kidney
deliveri
system
disassembl
final
optim
deliveri
system
achiev
without
compromis
sirna
genesilenc
activ
specif
anoth
major
issu
studi
use
oligonucleotid
clinic
toxic
toxic
oligonucleotidebas
therapeut
induc
hydrid
two
way
excess
silenc
intend
gene
product
reduct
express
unintend
target
antisens
mechan
first
type
toxic
usual
avoid
select
gene
product
critic
surviv
case
usual
easili
detect
earli
preclin
stage
second
type
toxic
base
low
probabl
short
rnai
sequenc
perfect
almost
perfect
match
one
site
genom
eventu
minim
perform
complet
blast
search
match
site
transcriptom
select
uniqu
sequenc
drug
candid
nevertheless
potenti
unintend
ote
probabl
greater
initi
expect
mention
section
sirna
two
differ
strand
administ
sens
antisens
potenti
abl
elicit
unwant
effect
addit
sinc
perfect
match
need
socal
seed
region
allow
mani
potenti
bind
site
full
complementar
requir
therefor
issu
fulli
address
appropri
complet
toxic
studi
add
level
complex
mani
perhap
toxic
elicit
oligonucleotid
relat
hybridizationindepend
effect
class
effect
relat
chemic
characterist
compound
mani
known
relat
interact
oligonucleotid
protein
induc
toxic
prolong
activ
partial
thromboplastin
time
activ
complement
immunostimul
class
effect
also
sequenc
depend
induc
stimul
innat
immun
review
levin
henri
mani
group
found
strike
differ
toxic
profil
rodent
nonhuman
primat
differ
due
biolog
differ
speci
exampl
pattern
tlr
express
differ
rodent
human
express
human
myeloid
cell
lack
mice
etc
addit
mani
case
also
import
speciesdepend
sequenc
differ
oligonucleotidebas
drug
perfectli
complementari
human
target
may
hybrid
correspond
mrna
anim
speci
use
toxic
studi
case
might
appropri
design
synthes
surrog
oligonucleotid
speciesspecif
drug
complementari
mrna
target
gene
relev
anim
speci
howev
ultim
critic
evalu
immunolog
properti
candid
nucleic
acid
drug
human
primari
immun
cell
known
synthet
process
understood
synthesisrel
impur
predict
speciesspecif
oligonucleotid
similar
chemistri
manufactur
control
sequenc
use
clinic
trial
anim
sequenc
surrog
could
test
alongsid
human
sequenc
toxic
studi
establish
biolog
effect
due
excess
silenc
target
gene
whether
possibl
toxic
rodent
immunostimul
would
clinic
relev
human
concept
part
toxic
profil
antisens
drug
last
decad
case
surrog
drug
need
simpli
target
exist
complet
differ
function
speci
toxic
studi
perform
also
case
target
mrna
deriv
infecti
agent
present
host
anoth
import
consider
drug
oligonucleotid
sequenc
mismatch
human
mrna
target
correspond
anim
speci
use
toxicolog
studi
one
two
mismatch
near
termini
sirna
mismatch
within
seed
sequenc
possibl
would
still
silenc
effect
ie
degre
activ
larg
depend
placement
mismatch
might
larg
target
specif
gener
recommend
case
test
whether
slight
differ
sequenc
reflect
activ
compound
case
believ
would
need
use
surrog
sequenc
character
unwant
effect
due
excess
pharmacolog
effect
hand
mismatch
great
impact
activ
compound
would
prefer
chang
mismatch
nucleotid
confer
full
sequenc
complementar
run
toxicolog
studi
surrog
complet
new
speciesspecif
sequenc
design
analys
toxic
effect
parallel
humanspecif
one
answer
question
broad
impact
candid
sequenc
choic
develop
process
cost
increas
dramat
full
toxicolog
studi
need
humanspecif
surrog
sequenc
parallel
scope
toxic
studi
surrog
molecul
use
includ
pharmacolog
studi
subchron
chronic
studi
reproduct
toxic
studi
immunotox
studi
even
carcinogen
studi
shortterm
assay
safeti
pharmacolog
studi
short
antisens
effect
wide
perform
case
surrog
except
safeti
pharmacolog
endpoint
includ
chronic
subchron
studi
design
toxic
studi
surrog
drug
becom
necessari
decid
whether
run
full
doserespons
curv
surrog
human
sequenc
practic
purpos
human
reason
argu
use
singl
activ
dose
surrog
unless
mark
toxic
associ
reduct
target
protein
rnaibas
therapeut
agent
current
develop
chemic
synthes
none
produc
biolog
reaction
result
compound
regul
biolog
tradit
drug
test
nonclin
assay
like
small
molecul
complet
toxic
character
genotox
safeti
pharmacolog
subchron
appropri
indic
chronic
toxic
carcinogen
assay
nevertheless
aspect
oligonucleotidebas
therapeut
much
akin
biolog
could
cover
intern
confer
harmonis
guidanc
exampl
chemic
character
compound
often
show
complex
profil
similar
biolog
tradit
drug
addit
metabol
similar
catabol
biolog
reduc
amino
acid
oligonucleotidebas
drug
cut
nucleotid
nucleas
order
maxim
return
rnaibas
drug
develop
program
compani
within
field
invest
consider
resourc
retain
strong
intellectu
properti
portfolio
protect
franchis
use
rnai
claim
mani
patent
led
signific
number
litig
compani
compet
ownership
emerg
technolog
fierc
competit
field
market
evolv
compani
seek
file
patent
base
structur
chemic
modif
well
specif
therapeut
target
deliveri
rna
structur
still
major
hurdl
field
recent
year
signific
number
new
patent
applic
file
yet
number
issu
patent
remain
small
sever
key
patent
patent
famili
field
rnai
therapeut
fire
mello
tuschl
iii
kreutzerlimm
iii
benitec
crook
glover
hannon
strongest
patent
portfolio
develop
alnylam
pharmaceut
sirna
therapeut
merck
mani
small
rnai
player
chosen
negoti
licens
deal
one
other
develop
proprietari
intellectu
properti
await
outcom
socal
fundament
patent
applic
one
semin
patent
enabl
develop
sirna
therapeut
file
nobel
laureat
andrew
fire
craig
mello
associ
own
carnegi
institut
washington
univers
massachusett
issu
wide
licens
nonexclus
basi
semin
patent
includ
first
second
tuschl
patent
famili
tuschl
ii
first
tuschl
patent
tuschl
jointli
file
thoma
tuschl
philip
zamor
philip
sharp
david
bartel
patent
cover
therapeut
applic
rnai
technolog
particular
use
sirna
sequencespecif
inhibit
gene
express
work
carri
tuschl
scientif
advisor
alnylam
pharmaceut
led
new
patent
tuschl
ii
describ
abil
synthet
sirna
induc
rnai
add
requir
overhang
key
patent
includ
kreutzerlimm
seri
cover
variou
oligonucleotid
structur
sirna
direct
toward
diseas
target
howev
first
grant
european
patent
belong
famili
recent
revok
other
undergo
complex
opposit
prosecut
procedur
alnylam
pharmaceut
launch
program
interferx
grant
licens
develop
rnai
therapeut
compani
broad
portfolio
issu
pend
patent
right
relat
sirna
molecul
use
therapeut
alnylam
pharmaceut
also
offer
nontherapeut
licens
agreement
life
scienc
reagent
servic
provid
interest
rnai
first
began
develop
patent
surfac
australian
compani
benitec
describ
use
transcrib
rna
induc
rnai
prioriti
date
back
fire
mello
use
anim
human
dsrna
sequenc
one
strand
match
target
mrna
deliv
cell
initi
silenc
process
benitec
call
dnadirect
rnai
ddrnai
howev
exampl
initi
given
work
plant
subsequ
patent
applic
work
expand
includ
mammalian
cell
compani
encount
number
legal
difficulti
primarili
result
disput
variou
jurisdict
nucleon
inc
benitec
number
license
includ
strateg
crosslicens
alnylam
pharmaceut
combimatrix
corpor
compani
also
start
appli
discoveri
mirna
diagnost
therapeut
lead
compani
field
begin
defin
posit
seek
form
strong
allianc
academ
institut
earli
possibl
key
patent
mirna
appli
max
planck
institut
includ
tuschl
iii
protect
use
specif
mirna
viral
hepat
rockefel
univers
univers
massachusett
medic
school
john
hopkin
univers
alnylam
pharmaceut
isi
exclus
colicense
tuschl
iii
seri
howev
patent
yet
grant
relat
mirna
base
therapeut
diagnost
licens
key
patent
own
alnylam
pharmaceut
isi
sirna
therapeut
purpos
rosetta
genom
exiqon
asuragen
stratagen
diagnost
interest
regulu
therapeut
joint
ventur
isi
pharmaceut
alnylam
pharmaceut
creat
discov
develop
commerci
mirna
therapeut
addit
rnai
technolog
lead
compani
also
submit
applic
cover
specif
diseas
target
nevertheless
segment
industri
view
claim
gene
target
uncompetit
patent
may
challeng
vigor
date
therapeuticbas
compani
hold
patent
regard
targetspecif
rnai
deliveri
rnai
compound
remain
unsolv
problem
shortli
discoveri
rnai
rapidli
emerg
novel
therapeut
approach
treat
human
diseas
rnaibas
therapeut
hold
promis
significantli
expand
number
druggabl
target
overcom
major
limit
exist
drug
compani
move
invest
grow
field
base
endogen
mechan
highli
specif
potent
overcom
obstacl
describ
remain
one
crucial
challeng
road
bring
rnaibas
drug
market
given
immens
resourc
invest
improv
safeti
efficaci
deliveri
come
year
like
present
excit
advanc
toward
use
rnaibas
therapeut
treatment
increas
number
patholog
otherwis
undrugg
exist
therapi
